Drug Profile

GRT 001

Alternative Names: GRT-001

Latest Information Update: 02 Jul 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator University of Regensburg
Developer Granite Bio
Class Anti-inflammatories; Monoclonal antibodies
Mechanism of Action Antibody-dependent cell cytotoxicity; Monocyte inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I Ulcerative colitis
Preclinical Inflammatory bowel diseases

Most Recent Events

24 Apr 2025 Preclinical trials in Inflammatory bowel diseases in Switzerland (unspecified route) (Granite Bio Pipeline, May 2025)
24 Apr 2025 Pharmacodynamic and adverse event data from a preclinical study in inflammation released by Granite Bio
24 Apr 2025 Granite Bio plans a phase Ib trial for Inflammatory bowel disease by the end of 2025

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com